**Supplementary Table**. Duke CustomID COVID-19 Page Hits and Edits

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Page name | Date of initial posting | Total Hits | Total Edits | Hits/Edits Ratio |
| All Guideline pages (N=7) |  | 8311 | 195 | 42 |
| Adult Hospitalized COVID Guideline | 3/20/2020 | 4120 | 29 | 142 |
| Ambulatory COVID Guideline | 12/29/2021 | 1152 | 11 | 104 |
| COVID Research Protocols | 3/23/2020 | 1282 | 133 | 9 |
| Pediatric COVID Guideline | 3/24/2020 | 502 | 13 | 38 |
| COVID Prophylaxis Guideline | 3/20/2020 | 330 | 4 | 82 |
| COVID Antimicrobial Guideline | 3/20/2020 | 254 | 3 | 84 |
| Asymptomatic COVID Guideline | 1/17/2022 | 106 | 1 | 106 |
| All Drug pages (N=8) |  | 8247 | 134 | 61 |
| COVID Monoclonal Antibodies | 11/10/2020 | 2659 | 50 | 68 |
| Remdesivir | 5/12/2020 | 2216 | 23 | 96 |
| COVID Vaccines | 12/12/2020 | 1478 | 32 | 46 |
| Baricitinib | 11/20/2020 | 1021 | 7 | 145 |
| Tocilizumab | 7/1/2021 | 297 | 8 | 37 |
| Paxlovid | 12/22/2021 | 272 | 5 | 54 |
| Molnupiravir | 12/27/2021 | 179 | 4 | 44 |
| Convalescent Plasma | 8/31/2020 | 125 | 5 | 25 |

Legend: Total hits and edits for each COVID-19 specific page relative to date of initial posting.

**Supplementary Images of CustomID Pages**





